Age Related Macular Degeneration – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Age Related Macular Degeneration – Pipeline Review, H2 2019’, provides an overview of the Age Related Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration

The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4D Molecular Therapeutics Inc

Abpro Corp

Abzyme Therapeutics LLC

Achillion Pharmaceuticals Inc

Acucela Inc

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Aevitas Therapeutics Inc

Affilogic SAS

Aibios Co Ltd

Aldeyra Therapeutics Inc

Alimera Sciences Inc

Alkahest Inc

Alkeus Pharmaceuticals Inc

Allegro Ophthalmics LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Alpine Biotherapeutics Corp

Alteogen Inc

Alzheon Inc

Amarantus Bioscience Holdings Inc

Amarna Therapeutics BV

Amyndas Pharmaceuticals LLC

AngioGenex Inc

Anida Pharma Inc

Annexon Inc

Apellis Pharmaceuticals Inc

Apexian Pharmaceuticals Inc

Apexigen Inc

Applied Genetic Technologies Corp

AptaBio Therapeutics Inc

Aptamer Sciences Inc

Ascentage Pharma Group International

Asclepiumm Taiwan Co Ltd

AsclepiX Therapeutics Inc

Astellas Pharma Inc

AVEO Oncology Inc

Avixgen Inc

Beijing Eastern Biotech Co Ltd

BellBrook Labs LLC

Benitec Biopharma Ltd

Beta Therapeutics Pty Ltd

Bio-Thera Solutions Ltd

BIOCND Inc

Biocure Technology Inc

Bioeq GmbH

Biogen Inc

Biokine Therapeutics Ltd

Biomics Biotechnologies Co Ltd

Biophytis SA

Boehringer Ingelheim International GmbH

Bridge Biotherapeutics Inc

Cadila Healthcare Ltd

Catalyst Biosciences Inc

Cell Care Therapeutics Inc

Cell Cure Neurosciences Ltd

Cell Medica Ltd

Celon Pharma SA

Charlesson LLC

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Chong Kun Dang Pharmaceutical Corp

CHS Pharma Inc

Cinnagen Co

Cipla BioTec Pvt Ltd

CJ HealthCare Corp

Clayton Biotechnologies Inc

Clearside BioMedical Inc

Clover Biopharmaceuticals

Coherus BioSciences Inc

CureLab Oncology Inc

Daiichi Sankyo Co Ltd

DNX Biopharmaceuticals Inc

Dobecure SL

Dong-A Socio Holdings Co Ltd

EirGenix Inc

Elasmogen Ltd

Elsalys Biotech SA

Envisia Therapeutics Inc

Enzene Biosciences Ltd

Epygen Biotech Pvt Ltd

Everglades Biopharma LLC

Exonate Ltd

Eye Co Pty Ltd

Eyedesis Biosciences LLC

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyestem Research Pvt Ltd

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Feramda Ltd

FirstString Research Inc

Formycon AG

Galimedix Therapeutics Ltd

Gemini Therapeutics Inc

Gene Signal International SA

Gene Techno Science Co Ltd

Genentech Inc

Generium

GenSight Biologics SA

Graybug Vision Inc

Gyroscope Therapeutics Ltd

Hanlim Pharm Co Ltd

Hemera Biosciences Inc

Hengenix Biotech Inc

Huabo Biopharm Co Ltd

Huons Global Co Ltd

Ichor Therapeutics Inc

Iconic Therapeutics Inc

Ildong Pharmaceutical Co Ltd

Immupharma Plc

Inflammasome Therapeutics Inc

Innovent Biologics Inc

Ionis Pharmaceuticals Inc

Isarna Therapeutics GmbH

iTherapeutics Corp

iVeena LLC

IVERIC bio Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Kala Pharmaceuticals Inc

Kalos Therapeutics Inc

Katairo GmbH

Kodiak Sciences Inc

Kyowa Kirin Co Ltd

Lead Discovery Center GmbH

Lin Bioscience Inc

Lupin Ltd

Luye Pharma Group Ltd

Mabion SA

MacuCLEAR Inc

MeiraGTx Holdings Plc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mor Research Applications Ltd

Mperia Therapeutics Inc

NanoScope Technologies LLC

Nanoscope Therapeutics Inc

Neovacs SA

NeuBase Therapeutics Inc

NeuExcell Therapeutics Inc

NGM Biopharmaceuticals Inc

Novartis AG

NovelMed Therapeutics Inc

Novelty Nobility Inc

OccuRx Pty Ltd

Ocugen Inc

Ocular Therapeutix Inc

OcuNexus Therapeutics Inc

ODIN Biotech Partners LLC

OliX Pharmaceuticals Inc

Omeros Corp

ONL Therapeutics Inc

Opthea Ltd

Outlook Therapeutics Inc

Oxford BioMedica Plc

Oxstem Ltd

Oxurion NV

PanOptica Inc

Paras Biopharmaceuticals Finland Oy

Pfizer Inc

Phanes Therapeutics Inc

PharmAbcine Inc

Phio Pharmaceuticals Corp

Phision Therapeutics

PlantForm Corp

Pleryon Therapeutics Ltd

Polus Inc

Profarma

Promedior Inc

Qilu Pharmaceutical Co Ltd

Reflexion Pharmaceuticals Inc

Regen BioPharma Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Reliance Life Sciences Pvt Ltd

RemeGen Ltd

Retrotope Inc

RheinCell Therapeutics GmbH

Ribomic Inc

RiniSight Inc

Samsung Bioepis Co Ltd

SanBio Inc

SciFluor Life Sciences LLC

Semathera Inc

Senju Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Splash Pharmaceuticals Inc

Stealth BioTherapeutics Corp

Sumitomo Dainippon Pharma Co Ltd

Sustained Nano Systems LLC

Suzhou Kintor Pharmaceutical Inc

Suzhou Stainwei Biotech Inc

Sylentis SAU

Taejoon Pharm Co Ltd

Tarsius Pharma Ltd

TechnoPhage SA

TOT Biopharm Co Ltd

TRACON Pharmaceuticals Inc

Translatum Medicus Inc

TreeFrog Therapeutics SAS

Visgenx Inc

Wellstat Ophthalmics Corp

Xbrane Biopharma AB

Xcovery Holding Company LLC

YD Life Science Co

Zhejiang Doer Biologics Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Age Related Macular Degeneration Overview 9

Age Related Macular Degeneration Therapeutics Development 10

Age Related Macular Degeneration Therapeutics Assessment 47

Age Related Macular Degeneration Companies Involved in Therapeutics Development 59

Age Related Macular Degeneration Drug Profiles 111

Age Related Macular Degeneration Dormant Projects 478

Age Related Macular Degeneration Discontinued Products 496

Age Related Macular Degeneration Product Development Milestones 499

Appendix 507

List of Tables

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Age Related Macular Degeneration – Pipeline by 3SBio Inc, H2 2019

Age Related Macular Degeneration – Pipeline by 4D Molecular Therapeutics Inc, H2 2019

Age Related Macular Degeneration – Pipeline by Abpro Corp, H2 2019

Age Related Macular Degeneration – Pipeline by Abzyme Therapeutics LLC, H2 2019

Age Related Macular Degeneration – Pipeline by Achillion Pharmaceuticals Inc, H2 2019

Age Related Macular Degeneration – Pipeline by Acucela Inc, H2 2019

Age Related Macular Degeneration – Pipeline by AdAlta Ltd, H2 2019

Age Related Macular Degeneration – Pipeline by Adverum Biotechnologies Inc, H2 2019

Age Related Macular Degeneration – Pipeline by Aerie Pharmaceuticals Inc, H2 2019

List of Figures

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports